Edwards Lifesciences Q2 Sales Climb 13.6%, but a Tax Hit Slashes Net Income; IRS Proposes Over $2B in Adjustments
EW sits 24% above its 52-week low of $72.3.
Summary
Edwards Lifesciences reported Q2 2026 sales of $1.74 billion, up 13.6% year-over-year, but net income fell sharply because of a $188.2 million tax valuation allowance. The IRS proposed over $2 billion in additional taxable income for prior years, escalating a long-running transfer pricing dispute.
Key Events · Earnings and Guidance · EW
-
Q2 Sales Growth Offset by Tax Charge
Net sales rose 13.6% to $1.74 billion, driven by TAVR and TMTT products, but a $188.2 million valuation allowance from a California tax law change pushed the effective tax rate to 53.6%, causing net income to drop to $241.9 million from $333.2 million a year ago.
-
IRS Proposes $2.07 Billion in Tax Adjustments
The IRS issued final Notices of Proposed Adjustment seeking to increase U.S. taxable income by $233.5 million for 2018 (tax elections) and $625.3 million, $530.7 million, and $683.6 million for 2018-2020 (transfer pricing). The company expects a follow-on NOPA with 40% penalties in Q3 2026.
-
CEO Adopts 10b5-1 Trading Plan
CEO Bernard Zovighian adopted a Rule 10b5-1 plan on July 28, 2026, to sell up to 145,696 shares starting November 9, 2026, representing a potential sale of approximately $13.1 million at current prices.
-
VIE Consolidation and Autus Acquisition
The company consolidated a VIE developing heart failure therapies, recognizing a $19.9 million gain and $139.6 million in goodwill. It also acquired Autus Valve Technologies for $128.9 million, adding $52.0 million in goodwill and $102.9 million in IPR&D.
Analysis · EW · Industrial Applications And Services
Operational momentum was strong, with sales up 13.6%, yet a $188.2 million valuation allowance triggered by a California tax law change drove the effective tax rate to 53.6% and nearly halved net income. More critically, the IRS issued final Notices of Proposed Adjustment that seek to increase U.S. taxable income by over $2 billion for 2018–2020, with potential 40% penalties looming. While the company intends to contest, the sheer size of the proposed adjustments and the near-term penalty risk create significant financial uncertainty. The CEO's adoption of a 10b5-1 trading plan adds a modest overhang, but the tax disputes remain the dominant risk.
At the time of this filing, EW was trading at $90.01 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $51.6B. The 52-week trading range was $72.30 to $96.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.